NEW YORK (GenomeWeb) – Health technology company Tempus announced today that it will provide sequencing and analysis services to Rush University Medical Center to help advance its personalized cancer treatment efforts.
Registering provides access to this and other free content.
Already have an account?Login Now.
The US Food and Drug Administration has approved Kite Pharmaceuticals' CAR T-cell therapy for large B-cell lymphomas, the New York Times reports.
Kaiser Health News reports that gene therapies could cost more than a million dollars.
Worcester Polytechnic Institute researchers have received a grant to combine biology and computer science for high school students.
In Nature this week: variants associated with obsessive-compulsive disorder, review of key CRISPR enzymes, and more.
This webinar will discuss the benefits of using unique molecular indices to overcome some challenges associated with next-generation sequencing panels.
This webinar will discuss a molecular barcode-based error correction method that enables combined mutation detection and DNA copy number profiling through circulating tumor DNA sequencing.